Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22-75
SponsorParadromics

About this trial

The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.

Eligibility criteria

Qualifiers

Clinical diagnosis of a progressive neuromuscular disease or a neurological injury.

Clinical diagnosis of anarthria or severe dysarthria.

Wheelchair dependent with severely impaired upper limb function.

Has a reliable method of communication and the ability to read and understand the English language.

Disqualifiers

Cognitive impairment or psychiatric illness that could impact the ability to comply with study requirements, as determined by the Study Investigator.

Co-morbidities or an ongoing chronic medical condition that would impair the ability to comply with study requirements.

The presence of another implanted device, like a pacemaker, deep brain stimulator, or implantable pulse generator.

Requires, or is expected to require regular MRI scans for on-going medical conditions.

Trial design

Treatments tested in this trial

  • Connexus Brain-Computer Interface

Treatment groups

2 Participants
are divided into 1 treatment group

Sponsors and collaborators

Paradromics

Lead sponsor

University of Michigan

Collaborator

University of California, Davis

Collaborator

Massachusetts General Hospital

Collaborator